Sophie L. Larsen

Sophie L. Larsen

Auto-generated profile, based on publicly available information

Sophie L. Larsen

Department of Demography, University of California Berkeley, Berkeley, CA, USA

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 December 2024 in Nature Communications
Verified
Journal Article
Open access
PDF file
NKNatalya Kostandova
Natalya Kostandova
CSCatherine Schluth
Catherine Schluth
RARohan Arambepola
Rohan Arambepola
FAFatumah Atuhaire
Fatumah Atuhaire
SBSophie Bérubé
Sophie Bérubé
AWAmy Wesolowski
Amy Wesolowski
The emergence of SARS-CoV-2 into a highly susceptible global population was primarily driven by human mobility-induced introduction events. Especially in the early stages, understanding mobility was vital to mitigating the pandemic prior to widespread vaccine availability. We conducted a systematic review of studies published from January 1, 2020, to May 9, 2021, that used population-level human mobility data to understand SARS-CoV-2 transmission. Of the 5505 papers with abstracts screened, 232 were included in the analysis. These papers focused on a range of specific questions but were dominated by analyses focusing on the USA and China. The majority included mobile phone data, followed by Google Community Mobility Reports, and few included any adjustments to account for potential biases in population sampling processes. There was no clear relationship between methods used to integrate mobility and SARS-CoV-2 data and goals of analysis. When considering papers focused only on the estimation of the effective reproductive number within the US, there was no clear relationship identified between this measure and changes in mobility patterns. Our findings underscore the need for standardized, systematic ways to identify the source of mobility data, select an appropriate approach to using it in analysis, and reporting.

4 August 2023 in Science Advances
Verified
Journal Article
Open access
SLSoren L. Larsen
Soren L. Larsen
ISIkgyu Shin
Ikgyu Shin
JJJefrin Joseph
Jefrin Joseph
HWHaylee West
Haylee West
RARafael Anorga
Rafael Anorga
PMPamela P. Martinez
Pamela P. Martinez
SARS-CoV-2 vaccines have been distributed at unprecedented speed. Still, little is known about temporal vaccination trends, their association with socioeconomic inequality, and their consequences for disease control. Using data from 161 countries/territories and 58 states, we examined vaccination rates across high and low socioeconomic status (SES), showing that disparities in coverage exist at national and subnational levels. We also identified two distinct vaccination trends: a rapid initial rollout, quickly reaching a plateau, or sigmoidal and slow to begin. Informed by these patterns, we implemented an SES-stratified mechanistic model, finding profound differences in mortality and incidence across these two vaccination types. Timing of initial rollout affects disease outcomes more substantially than final coverage or degree of SES disparity. Unexpectedly, timing is not associated with wealth inequality or GDP per capita. While socioeconomic disparity should be addressed, accelerating initial rollout for all over focusing on increasing coverage is an accessible intervention that could minimize the burden of disease across socioeconomic groups.

28 May 2026 in medRxiv
Verified
Preprint
Open access
PDF file
SLSoren L. Larsen
Soren L. Larsen
JYJunke Yang
Junke Yang
EHErin M. Haslett
Erin M. Haslett
AAAlyssa Anastasi
Alyssa Anastasi
AVAnnika Venegas
Annika Venegas
PMPamela P. Martinez
Pamela P. Martinez
1 While SARS-CoV-2 and influenza continue to place a significant burden on population health, within-household differences in decisions towards vaccination and seeking care across these two pathogens, and across sociodemographic groups, remain largely unexplored. By conducting a household-level survey in Illinois, we found that many individuals made inconsistent decisions about vaccination: among all adults, 29% were vaccinated for only one of COVID-19 or influenza, and among those with children in the home, 39% lived with a child whose influenza or COVID-19 vaccination status differed from their own. A higher proportion of adults were vaccinated against COVID-19 compared to influenza, while the opposite was true for those younger than 18 years old. These differences hold even when accounting for disparities in coverage by age, race/ethnicity, political affiliation, and socioeconomic status. While vaccinated individuals consistently reported wanting to protect themselves or others, those who declined vaccination reported highly hetero-geneous reasons ranging from resource constraints to distrust or misconceptions about vaccination. These differences are even more pronounced for COVID-19, with larger partisan gaps and higher refusal driven by safety concerns, lack of trust, or religious reasons than those who decide not to get the influenza vaccine. In contrast to vaccination, the decision to seek medical care when sick showed opposite sociodemographic trends, that are likely attributable to illness severity. Our findings highlight that closing gaps in COVID-19 and influenza vaccination coverage will require an integrative strategy that accounts for diverse motivations, fears, and barriers to access, while addressing social inequalities common to both diseases.

11 December 2024 in medRxiv
Verified
Preprint
Open access
PDF file
SLSophie L. Larsen
Sophie L. Larsen
JYJunke Yang
Junke Yang
HLHuibin LYU
Huibin LYU
YHYang Wei Huan
Yang Wei Huan
QTQiwen Teo
Qiwen Teo
PMPamela P. Martinez
Pamela P. Martinez
Despite the increased availability of serological data, understanding serodynamics remains challenging. Serocatalytic models, which describe the rate of seroconversion (gain of antibodies) and serore-version (loss of antibodies) within a population, have traditionally been fit to cross-sectional serological data to capture long-term transmission dynamics. However, a key limitation is their binary assumption on serological status, ignoring heterogeneity in optical density levels, antibody titers, and/or exposure history. Here, we implemented Gaussian mixture models - an established statistical tool - to cross-sectional data in order to characterize serological diversity of seasonal human coronaviruses (sHCoVs) throughout the lifespan. These methods identified four (NL63, 229E, OC43) to five (HKU1) distinct seropositive levels, suggesting that among seropositive individuals, the number of prior exposures or response to infection may vary. For each sHCoV, we fit adapted, multi-compartment serocatalytic models across 10 scenarios with different assumptions on exposure history and waning of antibodies. The best fit model for each sHCoV was always one that accounted for a gradient of seropositivity as well as host variation in the scale of serological response to infection. These models allowed us to estimate the strength and frequency of serological responses across sHCoVs, finding that the time for a seronegative individual to become seropositive ranges from 2.33-4.07 years across sHCoVs, and most individuals mount a strong antibody response reflected in high optical density values, skipping lower levels of seropositivity. We also find that despite frequent infection and strong serological responses, it is rare for an individual to remain seropositive throughout the lifetime. Crucially, our reimagined serocatalytic methods can be flexibly adapted across pathogens, having the potential to be broadly applied beyond this work.

8 April 2026 in medRxiv
Verified
Preprint
Open access
PDF file
ANAnjalika Nande
Anjalika Nande
SLSoren L Larsen
Soren L Larsen
JTJames Turtle
James Turtle
JDJessica T. Davis
Jessica T. Davis
SBShraddha Ramdas Bandekar
Shraddha Ramdas Bandekar
STShaun Truelove
Shaun Truelove
Six years after its emergence, SARS-CoV-2 continues to have a substantial burden, however, the impact of vaccination and the optimal timing of its rollout remain uncertain. To explore these uncertainties, the US Scenario Modeling Hub convened its 19th round of ensemble projections for COVID-19 hospitalizations and deaths in the United States. Eight teams provided outcomes for each US state and nationally from April 2025 to April 2026 under five scenarios regarding vaccine recommendations and timing. We assessed recommendations with two eligibility scenarios (high-risk individuals only and all-eligible) and two timing scenarios (classic start: mid-August, earlier start: late June). These were crossed to create four scenarios and were compared against a counterfactual scenario with no vaccination. We found that compared to no vaccination, our ensemble projections estimated 90,000 (95% PI 53,000-126,000) hospitalizations averted in the high-risk and classic timing scenario across the US. Expanding coverage averted an additional 26,000 (95% PI 14,000-39,000) hospitalizations, which when coupled with earlier vaccination timing further reduced national hospitalizations by 15,000 (95% PI −3,000-33,000). These findings estimate significant benefits from a broad all-eligible vaccination recommendation, and suggest an additional benefit is likely to be gained from an earlier vaccination campaign.

9 October 2025 in Epidemics
Verified
Journal Article
Open access
SLSoren L. Larsen
Soren L. Larsen
JYJunke Yang
Junke Yang
HLHuibin LYU
Huibin LYU
YHYang Wei Huan
Yang Wei Huan
QTQi Wen Teo
Qi Wen Teo
PMPamela P. Martinez
Pamela P. Martinez
Despite the increased availability of serological data, understanding serodynamics remains challenging. Serocatalytic models, which describe the rate of seroconversion (gain of antibodies) and seroreversion (loss of antibodies) within a population, have traditionally been fit to cross-sectional serological data to capture long-term transmission dynamics. However, a key limitation is their binary assumption on serological status, ignoring heterogeneity in optical density levels, antibody titers, and/or exposure history. Here, we implemented Gaussian mixture models - an established statistical tool - to cross-sectional data in order to characterize serological diversity of seasonal human coronaviruses (sHCoVs) across a wide range of age groups. These methods consistently identified multiple distinct seropositive levels, suggesting that among seropositive individuals, the number of prior exposures or response to infection may vary. We fit adapted, multi-compartment serocatalytic models with different assumptions on exposure history and waning of antibodies. The best fit model for each sHCoV was always one that accounted for host variation in the scale of serological response to infection. These models allowed us to estimate the strength and frequency of serological responses, finding that the time for a seronegative individual to become seropositive ranges from 2.40 to 7.03 years across sHCoVs, and most individuals mount a strong antibody response reflected in high optical density values, skipping lower levels of seropositivity. We find that despite frequent infection and strong serological responses, for all sHCoVs except 229E, individuals are likely to become seronegative again at some point after their first infection. Nonetheless, our results also indicate that by age 22, for each sHCoV the probability of having seroconverted at least once is over 95%. Crucially, our reimagined serocatalytic methods can be flexibly adapted across pathogens, having the potential to be broadly applied beyond this work.